Reduces elevated intraocular pressure (IOP). ANDA 203767, held by Micro Labs. Travoprost.
As of Nov 16, 2026, ANDA 203767 (Travoprost), held by Micro Labs, was first approved by FDA on Mar 19, 2021, with 0 approved supplements and 0 published complete response letters.
Travoprost ophthalmic solution 0.004% (ionic buffered solution) is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 19, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Travoprost0.004% · solution/drops;ophthalmic | Travoprost | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters